PDF herunterladen
Arthritis und Rheuma 2006; 26(02): 109-112
DOI: 10.1055/s-0037-1618542
Spezielle Fälle – alltägliche Probleme
Schattauer GmbH

Anakinra bei zwei Kindern mit therapieresistenter systemischer juveniler idiopathischer Arthritis

Anakinra in two children with refractory systemic juvenile idiopathic arthritis
Angelika Kropp
1   Deutsches Zentrum für Kinder- und Jugendrheumatologie (Ärztlicher Direktor: Dr. med. Hartmut Michels)
,
Hans-Otto Kettner
1   Deutsches Zentrum für Kinder- und Jugendrheumatologie (Ärztlicher Direktor: Dr. med. Hartmut Michels)
,
Hartmut Michels
1   Deutsches Zentrum für Kinder- und Jugendrheumatologie (Ärztlicher Direktor: Dr. med. Hartmut Michels)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
21. Dezember 2017 (online)

    Lizenzen und Reprints

Zusammenfassung

Zwei Kinder mit therapieresistenter systemischer juveniler idiopathischer Arthritis wurden erfolgreich mit Anakinrabehandelt. Die Tagesdosis lag zwischen 0,6 und 1,6 mg/kg s.c. Eine Dosisreduktion um 50 Prozent führte nicht zu einer Reaktivierung. Lokalreaktionen an der Injektionsstelle besserten sich dosisabhängig.

Summary

Two children with refractory systemic juvenile idiopathic arthritis have been successfully treated with Anakinra. The effective dosage varied between 0,6 mg and 1,6 mg/kg body weight/day subcutaneously. No relapse after a dose reduction of 50% has been seen. Skin reactions on injection sites were dose-dependent and could be diminished to a tolerable degree by dose reduction.

Schlüsselwörter

Systemische juvenile idiopathische Arthritis - Anakinra - Nebenwirkungen

Keywords

Systemic juvenile idiopathic arthritis - Anakinra - side effects
 

  • Literatur

  • 1 Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 612-6.
    CrossrefPubMedGoogle Scholar
  • 2 Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004; 8: 1-105.
    PubMedGoogle Scholar
  • 3 Fitzgerald AA, Leclercq SA, Yan A. et al Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52: 1794-803.
    CrossrefPubMedGoogle Scholar
  • 4 Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2004; 50: 2708-9.
    CrossrefPubMedGoogle Scholar
  • 5 Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-12.
    CrossrefPubMedGoogle Scholar
  • 6 Henrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum 2004; 50: S 438.
    Google Scholar
  • 7 Irigoyen PI, Olson J, Horn C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004; 50: S437-S438.
    Google Scholar
  • 8 Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005; 52: 1283-6.
    CrossrefPubMedGoogle Scholar
  • 9 Michels H. What is low-dose corticosteroid therapy in juvenile idiopathic arthritis?. Z Rheumatol 2000; 59 (Suppl. 02) Suppl. II/127-II/130.
    CrossrefPubMedGoogle Scholar
  • 10 Michels H. Juvenile idiopathische Arthritis – wann brauchen wir Glucocorticoide?. Akt Rheumatol 2005; 30: 183-6.
    Artikel in Thieme ConnectGoogle Scholar
  • 11 Pascual V, Allantaz F, Arce E. et al Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
    CrossrefPubMedGoogle Scholar
  • 12 Petty RE, Cassidy JT. Systemic Arthritis. In Cassidy JT, Petty R E, Laxer R, Lindsley C B. Hrsg. Textbook of Pediatric Rheumatology. Philadelphia: Elsevier Saunders; 2005: 291-303.
    Google Scholar
  • 13 Petty RE, Southwood TR, Manners P. et al International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
    Google Scholar
  • 14 Quartier P, Taupin P, Bourdeaut F. et al Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-101.
    CrossrefPubMedGoogle Scholar
  • 15 Stoeber E. Corticosteroid treatment of juvenile chronic polyarthritis over 22 years. Eur J Pediatr 1976; 121: 141-7.
    CrossrefPubMedGoogle Scholar
  • 16 Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
    Google Scholar
  • 17 Vogel-Gerlicher P, Kettner HO, Michels H. Etanercept – wann und wann nicht? Eine Übersicht. Akt Rheumatol 2005; 30: 191-4.
    Artikel in Thieme ConnectGoogle Scholar
  • 18 Woo P, Southwood TR, Prieur AM. et al Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849-57.
    CrossrefPubMedGoogle Scholar
  • 19 Yokota S, Miyamae T, Imagawa T. et al Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-25.
    CrossrefPubMedGoogle Scholar